Pancreatic cancer and clinical trials

Wednesday, July 17, 2019

Pancreatic cancer and clinical trials

David H. Henry, MD, host of Blood & Cancer, is on location at the 2019 annual meeting of the American Society of Clinical Oncology during this podcast, speaking with Davendra Sohal, MD, of the Cleveland Clinic. Dr. Sohal presented preliminary results from SWOG S1505, a phase 2 study on neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma.

Plus, in Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, talks about what happens when a cancer patient wants to act against medical advice.

Show Notes

By Emily Bryer, DO, resident in the department of internal medicine, University of Pennsylvania, Philadelphia

SWOG S1505 trial: Neoadjuvant chemotherapy experience with mFOLFIRINOX vs. gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.

  • Patients with resectable pancreatic adenocarcinoma typically have surgery prior to chemotherapy.
  • Many patients with pancreatic adenocarcinoma recur after surgery.
  • Randomized phase 2 trial of resectable pancreatic adenocarcinoma
    • Patients were given chemotherapy for 3 months. If there was no progression, patients underwent surgery, followed by more chemotherapy.
    • About one-third of these patients were found to have nonresectable disease.
    • Additional data will be published in 2020.
  • Neoadjuvant chemotherapy may be easier to tolerate since it is given prior to surgery.
  • Venous thromboembolism is a common among patients with metastatic pancreatic cancer.


SWOG S1505 trial: NCT02562716

ASCO 2019, Abstract 4137

For more MDedge Podcasts, go to

Email the show: [email protected]

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Ilana Yurkiewicz on Twitter: @ilanayurkiewicz

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.
Ilana Yurkiewicz, MD
Ilana Yurkiewicz, MD, is a fellow in hematology and oncology at Stanford University, where she also completed her internal medicine residency. Dr. Yurkiewicz holds an MD from Harvard Medical School and a BS from Yale University. She went into hematology and oncology because of the high-stakes decision-making, meaningful relationships with patients, and opportunity to help people through some of the toughest challenges of their lives. Dr. Yurkiewicz is also a medical journalist. She is a former AAAS Mass Media Fellow and Scientific American blog columnist, and her writing has appeared in numerous media outlets including Hematology News, where she writes the monthly column Hard Questions. Dr. Yurkiewicz is on Twitter: @ilanayurkiewicz. Dr. Yurkiewicz has no relevant conflicts of interest.